2024-02-22 15:07:31
The major discovery by an expert from the Cancer Research Institute of the University of Sherbrooke could enable more effective treatments against pancreatic cancer.
The important scientific breakthrough of professor-researcher Marie-Josée Boucher was achieved within the framework of fundamental laboratory research.
According to the University of Sherbrooke, it would make it possible to combine two therapeutic strategies (…) to reduce resistance to chemotherapy treatments, we can read in a press release.
People who have pancreatic cancer often demonstrate physical resistance to chemotherapy. Ms. Boucher combined two therapies, gemcitabine and TFEB, which helps reduce resistance to chemotherapy treatments. The combination of these two treatments makes it possible to remarkably reduce not only the growth of pancreatic cancer cells, but also their ability to develop tumors, maintains the University of Sherbrooke.
Open in full screen mode
Professor-researcher at the Cancer Research Institute of the University of Sherbrooke Marie-Josée Boucher
Photo: Courtesy: University of Sherbrooke
This discovery is a first step, adds the researcher. Preclinical validation experiments will be essential. It will also be interesting to test whether targeting TFEB can also increase the response of pancreatic cancer cells to other chemotherapeutic agents used in the clinic, she says.
Citing Canadian statistics, the University of Sherbrooke estimates that one in 68 people, or 1.5% of the population, died from pancreatic cancer in 2023. The mortality rate has not changed in 20 years.
For 15 years now, Professor Boucher has devoted her research to this cancer, which shows one of the lowest survival rates.
1708761599
#Major #breakthrough #treatment #pancreatic #cancer #University #Sherbrooke